MUC16 and pancreatic neoplasm: To validate the measurements obtained using immunopurified MUC16 and PODXL (Figure 1B), we also tested E-/L-selectin binding to MUC16-expressing (PODXL-knockdown) and PODXL-expressing (MUC16-knockdown) SW1990 pancreatic cancer cells [11, 12].